Reuters today reported that a copy of the blockbuster biotech drug Enbrel (SB4) was recommended for approval in Europe on Friday, making it the second so-called biosimilar antibody medicine to win such a green light from the continent's regulators.

Paine and Ritchlin have reviewed the evidence that new bone formation is centered around enthesial sites and that such findings are evident in psoriatic arthritis as well as psoriasis patients without arthritis.

A team of Japanese investigators examine 126 patients with ANCA-associated renal vasculitis to see if ANCA levels would predict disease relapse.

Rheumatology News reports the results of a novel trial presented at the European Academy of Dermatology and Venereology meeting in Copenhagen.

The Journal of Clinical Investigation reports a potential decline in the number of medical researchers in the future.

Researchers at CHOP have published their investigations into the heritability of pediatric autoimmune diseases that affects roughly one in 12 persons.

Interstitial lung disease (ILD) is a common extra-articular manifestation of rheumatoid arthritis (RA). Its presence may portend grave outcomes for those affected. The prevalence of ILD in RA ranges from 7.7% to 44% depending on the assessment tools used.

Healio reported the newly announced grant recipients from the Lupus Foundation of America.

The PROMISSE (Predictors of Pregnancy Outcome: Biomarkers in Antiphospholipid Antibody Syndrome and Systemic Lupus Erythematosus) study has revealed several important lessons in lupus care.

The Wall Street Journal reports that new drug development offers hope for people with idiopathic pulmonary fibrosis, a rare, progressive fibrosing lung disorder that affects nearly 200,000 Americans, mostly middle-aged and older adults. 

The Rheumatology Research Foundation and Rheumatology News report that research projects funded by the National Institutes of Health (NIH) dropped by 52% from 2010 to 2014, while the number funded by private foundations fell by 29% over that period.

The etiology of systemic sclerosis (SSc) remains unclear, but appears to involve complex pathogenic interactions between the immune system, the vasculature and fibrotic processes.

Neutrophils are pivotal players in the innate immune response, but are seldom linked to the pathogenesis of inflammatory arthritis, including juvenile idiopathic inflammatory arthritis (JIA).

PNAS has reported the work of an international team of scientists from the University College Dublin and the University of Sheffield, who have studied DNA samples and biopsy samples from joints of over 1,000 rheumatoid arthritis patients in the UK and Ireland and determined the C5orf30 gene to be

Two longtime collaborators studying HIV/AIDS at the Cleveland Clinic and Case Western Reserve University have received an $18.5 million grant from the Richard J. Fasenmyer Foundation.

Dr. Steven Katz describes how NIAMS sets priorities for investing congressionally-appropriated funds.

Neutrophil extracellular traps (NETs) are first line defense tools used to trap microbial pathogens.

The European Scleroderma Trials and Research (EUSTAR) cohort has reported the results of their prospective study to identify onset symptoms and risk factors for skin sclerosis and digital ulcers (DUs) in early onset systemic sclerosis (SSc) patients.

Targeting B cells in systemic lupus erythematosus, the prototypic autoimmune disorder, has long been an attractive target for researchers. Despite negative trials with rituximab and the limited success of belimumab, efforts to inhibit B cell activity have continued.

Gout is the most common inflammatory arthritis affecting adults and, probably, one of the most underestimated.